CSPC Pharmaceutical Group Limited (CSPCY)
USD 3.05
(-2.71%)
USD 3.05
(-2.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.98 Billion CNY | 2.11% |
| 2022 | 7.55 Billion CNY | 10.88% |
| 2021 | 6.81 Billion CNY | 12.31% |
| 2020 | 6.07 Billion CNY | 31.96% |
| 2019 | 4.6 Billion CNY | 15.68% |
| 2018 | 3.97 Billion HKD | 37.71% |
| 2017 | 2.88 Billion HKD | 22.95% |
| 2016 | 2.34 Billion HKD | 33.7% |
| 2015 | 1.75 Billion HKD | 36.81% |
| 2014 | 1.28 Billion HKD | 33.47% |
| 2013 | 961.97 Million HKD | -47.93% |
| 2012 | 1.84 Billion HKD | 668.32% |
| 2011 | 240.43 Million HKD | -70.04% |
| 2010 | 802.49 Million HKD | -18.15% |
| 2009 | 980.39 Million HKD | 1.08% |
| 2008 | 969.91 Million HKD | 97.13% |
| 2007 | 492.01 Million HKD | 30568.23% |
| 2006 | 1.6 Million HKD | -98.97% |
| 2005 | 155.09 Million HKD | -41.4% |
| 2004 | 264.64 Million HKD | -58.48% |
| 2003 | 637.34 Million HKD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 2.03 Billion CNY | 3.3% |
| 2024 Q2 | 1.66 Billion CNY | 0.0% |
| 2023 Q4 | 1.96 Billion CNY | 1.78% |
| 2023 Q2 | 1.9 Billion CNY | 6.81% |
| 2023 Q1 | 1.78 Billion CNY | -8.3% |
| 2023 FY | 7.71 Billion CNY | 2.11% |
| 2023 Q3 | 1.93 Billion CNY | 1.44% |
| 2022 Q3 | 1.88 Billion CNY | -4.05% |
| 2022 FY | 7.55 Billion CNY | 10.88% |
| 2022 Q1 | 1.76 Billion CNY | -11.55% |
| 2022 Q2 | 1.96 Billion CNY | 11.07% |
| 2022 Q4 | 1.94 Billion CNY | 3.41% |
| 2021 Q4 | 1.99 Billion CNY | 8.39% |
| 2021 FY | 6.81 Billion CNY | 12.31% |
| 2021 Q3 | 1.84 Billion CNY | 6.52% |
| 2021 Q1 | 1.96 Billion CNY | 21.23% |
| 2021 Q2 | 1.73 Billion CNY | -11.93% |
| 2020 Q1 | 1.23 Billion CNY | 4.44% |
| 2020 Q4 | 1.62 Billion CNY | -8.81% |
| 2020 FY | 6.07 Billion CNY | 31.96% |
| 2020 Q3 | 1.77 Billion CNY | 14.44% |
| 2020 Q2 | 1.55 Billion CNY | 25.25% |
| 2019 Q1 | 1.32 Billion CNY | 37.7% |
| 2019 Q3 | 1.23 Billion CNY | -4.55% |
| 2019 Q4 | 1.18 Billion CNY | -3.67% |
| 2019 FY | 4.6 Billion CNY | 15.68% |
| 2019 Q2 | 1.29 Billion CNY | -2.41% |
| 2018 Q1 | 1.15 Billion CNY | 26.99% |
| 2018 Q2 | 1.09 Billion CNY | -5.53% |
| 2018 Q3 | 1.04 Billion CNY | -4.48% |
| 2018 Q4 | 960.74 Million CNY | -8.2% |
| 2018 FY | 3.97 Billion HKD | 37.71% |
| 2017 FY | 2.88 Billion HKD | 22.95% |
| 2017 Q4 | 913.3 Million CNY | -0.4% |
| 2017 Q3 | 916.94 Million CNY | 6.49% |
| 2017 Q2 | 861.08 Million CNY | 6.72% |
| 2017 Q1 | 806.89 Million CNY | 20.2% |
| 2016 Q3 | 676.17 Million CNY | 0.5% |
| 2016 Q4 | 671.27 Million CNY | -0.72% |
| 2016 Q2 | 672.77 Million CNY | 5.62% |
| 2016 FY | 2.34 Billion HKD | 33.7% |
| 2016 Q1 | 636.95 Million CNY | 15.34% |
| 2015 Q4 | 552.26 Million CNY | 0.87% |
| 2015 FY | 1.75 Billion HKD | 36.81% |
| 2015 Q3 | 547.48 Million CNY | -1.52% |
| 2015 Q2 | 555.94 Million CNY | 7.45% |
| 2015 Q1 | 517.41 Million CNY | 16.62% |
| 2014 Q4 | 443.68 Million CNY | 3.51% |
| 2014 FY | 1.28 Billion HKD | 33.47% |
| 2014 Q1 | 359.37 Million CNY | 10.98% |
| 2014 Q2 | 439.24 Million CNY | 22.22% |
| 2014 Q3 | 428.66 Million CNY | -2.41% |
| 2013 Q4 | 323.83 Million CNY | 13.18% |
| 2013 FY | 961.97 Million HKD | -47.93% |
| 2013 Q3 | 286.12 Million CNY | 9.68% |
| 2013 Q2 | 260.87 Million CNY | -18.68% |
| 2013 Q1 | 320.82 Million CNY | 0.0% |
| 2012 FY | 1.84 Billion HKD | 668.32% |
| 2011 FY | 240.43 Million HKD | -70.04% |
| 2010 FY | 802.49 Million HKD | -18.15% |
| 2009 FY | 980.39 Million HKD | 1.08% |
| 2008 FY | 969.91 Million HKD | 97.13% |
| 2007 FY | 492.01 Million HKD | 30568.23% |
| 2006 FY | 1.6 Million HKD | -98.97% |
| 2005 FY | 155.09 Million HKD | -41.4% |
| 2004 FY | 264.64 Million HKD | -58.48% |
| 2003 FY | 637.34 Million HKD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | 14.792% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | 59.511% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | 0.498% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 17670.402% |
| Novartis AG | 9.76 Billion USD | 28.539% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 99.807% |